The Manufacturers Life Insurance Company Buys 402 Shares of Luminex Corporation (LMNX)

The Manufacturers Life Insurance Company raised its stake in shares of Luminex Corporation (NASDAQ:LMNX) by 1.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,640 shares of the medical instruments supplier’s stock after purchasing an additional 402 shares during the quarter. The Manufacturers Life Insurance Company owned 0.07% of Luminex Corporation worth $668,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in Luminex Corporation by 13.0% during the first quarter. State Street Corp now owns 1,009,789 shares of the medical instruments supplier’s stock valued at $18,548,000 after purchasing an additional 116,351 shares in the last quarter. Bank of America Corp DE boosted its holdings in Luminex Corporation by 9.9% during the first quarter. Bank of America Corp DE now owns 322,154 shares of the medical instruments supplier’s stock valued at $5,917,000 after purchasing an additional 29,107 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Luminex Corporation by 7.9% during the second quarter. Teachers Advisors LLC now owns 94,401 shares of the medical instruments supplier’s stock valued at $1,994,000 after purchasing an additional 6,912 shares in the last quarter. Citigroup Inc. boosted its holdings in Luminex Corporation by 20.6% during the second quarter. Citigroup Inc. now owns 44,906 shares of the medical instruments supplier’s stock valued at $948,000 after purchasing an additional 7,658 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in Luminex Corporation by 52,547.0% during the first quarter. BlackRock Inc. now owns 5,063,064 shares of the medical instruments supplier’s stock valued at $93,008,000 after purchasing an additional 5,053,447 shares in the last quarter. 77.54% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “The Manufacturers Life Insurance Company Buys 402 Shares of Luminex Corporation (LMNX)” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2017/11/20/the-manufacturers-life-insurance-company-buys-402-shares-of-luminex-corporation-lmnx.html.

In other news, Director G Walter Loewenbaum II sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $21.79, for a total value of $1,089,500.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Robert J. Cresci sold 19,631 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total value of $372,596.38. Following the completion of the transaction, the director now directly owns 260,358 shares in the company, valued at $4,941,594.84. The disclosure for this sale can be found here. 6.90% of the stock is owned by insiders.

A number of equities research analysts have weighed in on the company. TheStreet raised Luminex Corporation from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. Jefferies Group LLC reaffirmed a “hold” rating and set a $21.00 price objective on shares of Luminex Corporation in a report on Friday, October 20th. ValuEngine raised Luminex Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Zacks Investment Research raised Luminex Corporation from a “hold” rating to a “strong-buy” rating and set a $22.00 price objective on the stock in a report on Thursday, August 24th. Finally, BidaskClub downgraded Luminex Corporation from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a strong buy rating to the company. Luminex Corporation has an average rating of “Hold” and an average target price of $20.00.

Luminex Corporation (NASDAQ:LMNX) opened at $21.51 on Monday. The company has a market capitalization of $947.61, a P/E ratio of 37.09, a PEG ratio of 2.70 and a beta of 0.18. Luminex Corporation has a 1-year low of $17.68 and a 1-year high of $22.27.

Luminex Corporation (NASDAQ:LMNX) last announced its earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 EPS for the quarter, topping the consensus estimate of $0.19 by $0.06. The business had revenue of $74.14 million for the quarter, compared to the consensus estimate of $74.38 million. Luminex Corporation had a return on equity of 6.01% and a net margin of 9.52%. Luminex Corporation’s revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.21 EPS. equities research analysts anticipate that Luminex Corporation will post 0.49 EPS for the current year.

About Luminex Corporation

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)

Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply